Introduction to C10orf95-AS1, A Potential Drug Target (G100505761)

Target Name: C10orf95-AS1

NCBI ID: G100505761

C10orf95-AS1

Other Name(s): C10orf95-AS1 variant 1 | RPARP-AS1 | C10orf95 antisense RNA 1, transcript variant 1 | C10orf95 antisense RNA 1

Introduction to C10orf95-AS1, A Potential Drug Target

C10orf95-AS1, also known as chromosome 10 open reading frame 95 antisense RNA 1, is a long non-coding RNA that has gained significant attention in recent years as a potential drug target or biomarker in various diseases. This article will delve into the characteristics of C10orf95-AS1, its implications in disease development, its potential as a drug target, and its utility as a biomarker for disease diagnosis, prognosis, and treatment response evaluation.

Characteristics of C10orf95-AS1

C10orf95-AS1 is located on human chromosome 10 and is transcribed in the antisense direction of the C10orf95 gene. It is a long non-coding RNA (lncRNA) comprising more than 2000 nucleotides. Although initially classified as a non-functional RNA molecule, emerging evidence suggests its involvement in various cellular processes.

Implications in Disease Development

C10orf95-AS1 has been implicated in the development and progression of several diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, dysregulation of C10orf95-AS1 expression has been observed in various types, such as breast, lung, colorectal, and pancreatic cancers. High levels of C10orf95-AS1 have been associated with tumor progression, metastasis, and poor patient prognosis. In neurodegenerative disorders, abnormal expression of C10orf95-AS1 has been linked to neuronal cell death, impaired synaptic functions, and the accumulation of protein aggregates. Additionally, altered levels of C10orf95-AS1 have been observed in cardiovascular diseases, where it is thought to be involved in the regulation of inflammation, oxidative stress, and vascular remodeling.

Potential as a Drug Target

The dysregulation of C10orf95-AS1 in various diseases highlights its potential as a therapeutic target. Strategies to target C10orf95-AS1 include its inhibition using antisense oligonucleotides (ASOs) or modulating its expression using small molecules or gene editing techniques. In preclinical studies, the downregulation of C10orf95-AS1 has shown promising outcomes, including inhibition of tumor growth, reduction in neurodegenerative pathology, and attenuation of cardiovascular disease progression. However, further research is needed to evaluate the safety and efficacy of targeting C10orf95-AS1 in clinical settings.

Utility as a Biomarker

C10orf95-AS1 also holds potential as a biomarker for disease diagnosis, prognosis, and treatment response evaluation. In cancer, its aberrant expression levels in tumor tissues and bodily fluids, such as blood or urine, have been associated with disease stage, aggressiveness, and patient survival. This suggests its potential use as a diagnostic and prognostic biomarker. Moreover, monitoring changes in C10orf95-AS1 expression during treatment can facilitate the evaluation of therapeutic response and help clinicians make informed decisions regarding treatment adjustments. In neurodegenerative disorders, the levels of C10orf95-AS1 in cerebrospinal fluid or brain tissues have shown promise as a biomarker for disease progression, allowing for early intervention and monitoring of treatment efficacy.

Conclusion

C10orf95-AS1 represents an exciting frontier in biomedical research, with its potential as both a drug target and a biomarker in various diseases. Its dysregulation in cancer, neurodegenerative disorders, and cardiovascular diseases suggests its pivotal role in disease development and progression. Strategies to target C10orf95-AS1 offer new therapeutic avenues, while its potential as a biomarker holds promise for disease diagnosis, prognosis, and treatment response evaluation. Continued research into the molecular mechanisms underlying its functions and clinical studies are essential to fully harness the therapeutic potential and utility of C10orf95-AS1 in precision medicine and personalized healthcare.

Protein Name: C10orf95 Antisense RNA 1

The "C10orf95-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C10orf95-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets